
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Combining TT125-802 With Osimertinib
Stefanie Fluckiger-Mangual outlines plans to test TT125-802 with osimertinib in EGFR-mutant lung cancer for deeper, longer responses.
Play episode from 06:22
Transcript


